304 related articles for article (PubMed ID: 32819251)
1. Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer's Disease: A Recent Update.
Pandey M; Choudhury H; Verma RK; Chawla V; Bhattamisra SK; Gorain B; Raja MAG; Amjad MW
CNS Neurol Disord Drug Targets; 2020; 19(9):648-662. PubMed ID: 32819251
[TBL] [Abstract][Full Text] [Related]
2. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticlized System: Promising Approach for the Management of Alzheimer's Disease through Intranasal Delivery.
Bahadur S; Sachan N; Harwansh RK; Deshmukh R
Curr Pharm Des; 2020; 26(12):1331-1344. PubMed ID: 32160843
[TBL] [Abstract][Full Text] [Related]
5. Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy.
Wong CYJ; Baldelli A; Hoyos CM; Tietz O; Ong HX; Traini D
Drug Deliv Transl Res; 2024 Jul; 14(7):1776-1793. PubMed ID: 38441832
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
Fonseca-Santos B; Gremião MP; Chorilli M
Int J Nanomedicine; 2015; 10():4981-5003. PubMed ID: 26345528
[TBL] [Abstract][Full Text] [Related]
7. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
[TBL] [Abstract][Full Text] [Related]
8. Intranasal drug delivery for treatment of Alzheimer's disease.
Fonseca LC; Lopes JA; Vieira J; Viegas C; Oliveira CS; Hartmann RP; Fonte P
Drug Deliv Transl Res; 2021 Apr; 11(2):411-425. PubMed ID: 33638130
[TBL] [Abstract][Full Text] [Related]
9. Nano-lipidic formulation and therapeutic strategies for Alzheimer's disease via intranasal route.
Tripathi S; Gupta U; Ujjwal RR; Yadav AK
J Microencapsul; 2021; 38(7-8):572-593. PubMed ID: 34591731
[TBL] [Abstract][Full Text] [Related]
10. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
[TBL] [Abstract][Full Text] [Related]
11. Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review.
Babu SR; Shekara HH; Sahoo AK; Harsha Vardhan PV; Thiruppathi N; Venkatesh MP
Ther Deliv; 2023 Sep; 14(9):571-594. PubMed ID: 37691577
[TBL] [Abstract][Full Text] [Related]
12. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
Islam SU; Shehzad A; Ahmed MB; Lee YS
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
[TBL] [Abstract][Full Text] [Related]
13. Targeted Nanoparticles for the Treatment of Alzheimer's Disease.
Martín-Rapun R; De Matteis L; Ambrosone A; Garcia-Embid S; Gutierrez L; de la Fuente JM
Curr Pharm Des; 2017; 23(13):1927-1952. PubMed ID: 28025949
[TBL] [Abstract][Full Text] [Related]
14. Nose-to-brain drug delivery for the treatment of Alzheimer's disease: current advancements and challenges.
A P; Agrawal M; Dethe MR; Ahmed H; Yadav A; Gupta U; Alexander A
Expert Opin Drug Deliv; 2022 Jan; 19(1):87-102. PubMed ID: 35040728
[TBL] [Abstract][Full Text] [Related]
15. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.
Jojo GM; Kuppusamy G; De A; Karri VVSNR
Drug Dev Ind Pharm; 2019 Jul; 45(7):1061-1072. PubMed ID: 30922126
[TBL] [Abstract][Full Text] [Related]
16. Biomaterials in treatment of Alzheimer's disease.
Agrawal M; Prathyusha E; Ahmed H; Dubey SK; Kesharwani P; Singhvi G; Naidu VGM; Alexander A
Neurochem Int; 2021 May; 145():105008. PubMed ID: 33684545
[TBL] [Abstract][Full Text] [Related]
17. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease.
Wong LR; Ho PC
J Pharm Pharmacol; 2018 Jan; 70(1):59-69. PubMed ID: 29034965
[TBL] [Abstract][Full Text] [Related]
18. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Sunena ; Singh SK; Mishra DN
Curr Drug Deliv; 2019; 16(1):51-58. PubMed ID: 30289074
[TBL] [Abstract][Full Text] [Related]
19. Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin.
Tashima T
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171799
[TBL] [Abstract][Full Text] [Related]
20. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
